Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Stand by, your program is about to begin. Hello and welcome everyone joining today's second quarter 2025 Cura Oncology Inc. Financial Results Conference call. At this time all participants are in a listen-only mode. Later you will have an opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star and 1 on your telephone keypad. Please note this call is being recorded. I am standing by should you need any assistance. It is now my pleasure to turn the meeting over to Greg Mann, SVP of Investor Relations and Corporate Affairs. Please go ahead. Thank you, Brittany. Good afternoon and welcome to Cura Oncology's second quarter 2025 conference call. Joining the call today are Dr. Troy Wilson, President and Chief Executive Officer, Dr. Molly Leone, Chief Medical Officer, Brian Powell, Chief Commercial Officer, and Tom Doyle, Senior Vice President of Finance and Accounting. Before I turn the call over to Dr. Wilson, we remind you that today's call will include forward-looking statements based on current expectations. Such statements represent management's judgment as of today and may involve risks and uncertainties that cause actual results to differ materially from expected results. Please refer to Cura's filings with the SEC which are available from the SEC or on the Cura Oncology website for information concerning risk factors that could affect the company. With that, I'll turn the call over to Troy. Thank you, Greg. Good afternoon and thank you all for joining us. At Cura, we're committed to transforming outcomes for patients with AML. Today, we'll provide updates on our global development progress for our lead programs of demented, regulatory status of our new drug application, preparations for com...